Table 3. Probabilistic sensitivity analysis considering four DCV/ASV prices.

	Total treatment cost ($US)	Total cost DCV/ASV ($US)	Total QALY DCV/ASV	Total cost PR ($US)	Total QALY PR	ICER a ($US/QALY)	Prob. of cost-effectiveness b
Local utility estimates	77,419	80,117				16,635	43,6%
	58,065	60,775	14.6	17,803	10.9	11,581	71,5%
	38,710	41,856				6,375	91,6%
	19,355	22,920				1,364	98,6%
Literature utility estimates	38,710	41,958	12.6	17,921	10.08	9,241	86.3%

PR: Peginterferon plus Ribavirin, PIs: Protease Inhibitors, DCV/ASV: Daclatasvir plus Asunaprevir, QALY: Quality Adjusted Life Years, ICER: Incremental cost effectiveness ratio, 1 $US = 620 CLP

^aMontecarlo simulation (5,000 iterations)

^bConsidering a suggested threshold of 1times GDP per capita